AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04794946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Covishield
Description: 2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
Study NCT04794946 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Covishield
Description: 2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
Study NCT05927272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SKIN SAMPLES
Description: At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh~Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq).
Study NCT05927272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BLOOD SAMPLES
Description: Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
Study NCT05974046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]IDV184001AN
Description: \[14C\]-IDV184001AN 200 mg/\~100 µCi/ 15 g oral suspension
Study NCT05927272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narrowband UVB
Description: narrowband UVB (Nb-UVB) 2 times a week
Study NCT05927272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Steroids
Description: Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
Study NCT05340322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colposcopy using pocket colpscope and thermocoagulator
Description: If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
Study NCT05779605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based training
Description: Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
Study NCT05779605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Center-based training
Description: Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
Study NCT05897112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A received cryotherpay
Description: Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
Study NCT05897112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B received 10% Potassium Hydroxide Solution
Description: Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
Study NCT05723679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeO2 gas mixture
Description: Low-density helium-oxygen gas mixture (HeO2: 21% O2 and 79% He). Participant will be breathing this gas mixture.
Study NCT05723679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room air gas mixture
Description: Normal room air
Study NCT04884867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based supportive skills delivered by phone by lay coaches
Description: 8-10 weekly coaching sessions delivered by telephone
Study NCT06428318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Sputum culture
Description: Sputum culture was done to patients and they received Antibiotics According to its results
Study NCT06428318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BioFire Pneumonia Panel (BFPP)
Description: BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
Study NCT05191303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile intervention of breastfeeding counseling
Description: The mobile intervention of breastfeeding counseling includes an evidence-based information of breastfeeding, which is based on Ten steps of breastfeeding of Baby Friendly Hospital Initiative (BFHI) and Finnish Institute for Health and Welfare recommendation. The links provide more information and videos related to breastfeeding topic. The mobile intervention of breastfeeding counseling allows the client to write comments or notes that can be used in counseling at maternity clinic or hospital. The mobile intervention of breastfeeding counseling also provides an e-mail to non-urgent questions related to breastfeeding. Questions will be answered within 3 or 4 days by a lactation consultant (IBCLC).
Study NCT05037669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PACE CART19
Description: PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
Study NCT05172037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Novaferon
Description: a novel recombinant antiviral protein drug
Study NCT05172037 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT04991493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride
Description: pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured.
Study NCT04991493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride
Description: pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured.
Study NCT04991493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia.
Study NCT02329093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: To MRI-detecting bone signal changes in radiographic hip OA
Description: To examine whether or not non-weight bearing reduced OA progression
Study NCT05188638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoftOx Inhaled Solution (SIS)
Description: SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
Study NCT05188638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile isotonic saline
Study NCT04877327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Cryotherapy and radiofrequency
Study NCT05501639 — intervention group
Intervention type: DRUG
Intervention: tiotropium
Description: tiotropium
Study NCT05501639 — intervention group
Intervention type: DRUG
Intervention: long-acting β2-agonists (LABA)
Description: long-acting β2-agonists (LABA)
Study NCT05501639 — intervention group
Intervention type: DRUG
Intervention: inhaled corticosteroids (ICS)
Description: inhaled corticosteroids (ICS)
Study NCT05268705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day diet
Description: The participants must follow a 7-day high-carbohydrate-low-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
Study NCT05268705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day diet
Description: The participants must follow a low-carbohydrate-high-fat-low-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
Study NCT05268705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7-day diet
Description: The participants must follow a low-carbohydrate-low-fat-high-protein diet before the inclinic study visit at day 8. The in-clinic study visits are identical for all the three study arms.
Study NCT06531226 — intervention group
Intervention type: OTHER
Intervention: Fill in personality questionnaires
Description: For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.
Study NCT05005221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated text messages
Description: Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
Study NCT05005221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated text messages
Description: Automated text messages will be used to facilitate blood sample collection at home for therapeutic drug monitoring of tacrolimus and mycophenolate. Participants will collect dried blood samples on 4 occasions. Two days in the clinical with simultaneous venipuncture (one sample) and two days at home with 4 samples collected at specified time points over 8 hours.
Study NCT04831905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-wave ablation
Description: Micro-wave ablation
Study NCT06103344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-7-8 Breathing Exercise Training
Description: Participants in the intervention group will be taught 4-7-8 breathing exercises collectively, and the training will be repeated on specified days (twice a week for a total of 4 weeks). During the training, it will be checked whether each participant in the intervention group can perform the breathing exercise correctly and feedback will be given. Participants who fail to implement the exercise will be excluded from the study. 4-7-8 breathing exercise training, prepared in accordance with the literature, will be given by the assistant researcher who has training and certification in breathing exercises. Training will be planned in an empty classroom, for approximately 20 minutes and at the students' end time. Thus, educational activities in the institution will not be disrupted.
Study NCT05585073 — intervention group
Intervention type: OTHER
Intervention: Whether lymph node dissection is qualified or not
Description: Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
Study NCT04417114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Statin
Study NCT04374279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 150 Mg Oral Tablet
Description: Bicalutamide 150 mg by mouth daily for 7 days
Study NCT05409768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short axis out of plane
Description: A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance short axis visualisation out of plane approaches.
Study NCT05409768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anteroposterior short axis in plane
Description: A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance anteroposterior short axis visualisation in plane approaches.
Study NCT05308615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhea® Health Tone
Description: Rhea® Health Tone
Study NCT05308615 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rhea® Health Tone
Description: Rhea® Health Tone
Study NCT05583838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
Study NCT05583838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
Study NCT06003777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522
Description: PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
Study NCT06003777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions as escalating single doses to be determined.
Study NCT05836272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine Bitartrate
Description: The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion.
Study NCT05836272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.
Study NCT06118424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: deepfake video
Description: The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
Study NCT05669040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological education
Description: Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
Study NCT05669040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training in the use of MyPlan Aplication
Description: Review of the use of the aplication
Study NCT05669040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Experience
Description: * How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind
Study NCT05554276 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
Description: All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
Study NCT02683018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoked Cannabis High CBD/low THC
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
Study NCT02683018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smoked Placebo Cannabis Low CBD/low THC
Description: Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
Study NCT05633108 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention will be administered.
Study NCT04700163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C144-LS and C-135-LS
Description: A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
Study NCT06332287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Trilaciclib and Pemetrexed
Description: This was a single-arm, exploratory study of the combination of Trilaciclib and Pemetrexed in patients with non-small cell lung cancer with leptomeningeal metastasis. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every six cycles to assess tumor response.
Study NCT05028049 — intervention group
Intervention type: DRUG
Intervention: Sufentanil injection
Description: Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
Study NCT05028049 — intervention group
Intervention type: DRUG
Intervention: Remifentanil Hydrochloride
Description: Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
Study NCT05028049 — intervention group
Intervention type: OTHER
Intervention: plain areas
Description: Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
Study NCT06266910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual training video
Description: The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment.
Study NCT06028828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given Day-5, Day-4, Day-3, Day-2
Study NCT06028828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given Day-5
Study NCT06028828 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Given Day-1
Study NCT06160596 — intervention group
Intervention type: GENETIC
Intervention: Long term survival multimodal analysis
Description: * To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)
Study NCT06266910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Visual training video
Description: The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment.
Study NCT05527600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: intensity of acute pain evaluation
Description: the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
Study NCT04782804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
Study NCT04782804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.